Bottom line
PBE vs BIB: the short answer
PBE (Invesco Biotechnology & Genome ETF) and BIB (ProShares Ultra Nasdaq Biotechnology) are quite different portfolios: only about 31% of their top holdings (by weight) are shared.
But BIB is far broader, holding 267 positions to 33 for PBE, so beyond the top names it adds exposure PBE doesn't have.
PBE is cheaper at 0.59% vs 0.95% — a difference of $36 a year per $10,000 invested.
Over five years, PBE returned +3.4% a year vs −1.0% for BIB.
Updated Nov 19, 2026
PBE vs BIB side by side
| PBE | BIB | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | Invesco | ProShares |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 0.59% | 0.95% |
| Annual cost per $10k | $59 | $95 |
| 10-yr cost on $10k (prospectus) | $738 | $1,401 |
| Max front load | None | None |
| 12b-1 fee | — | — |
| 1-yr return | +24.7% | +59.3% |
| 5-yr return (annualized) | +3.4% | −1.0% |
| 10-yr return (annualized) | +5.2% | +1.4% |
| Best quarter | +25.3% | +56.2% |
| Worst quarter | −24.3% | −42.7% |
| Net assets (fund) | $281.9M | $73.7M |
| Number of holdings | 33 | 267 |
| Portfolio turnover | 103% | 29% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | PBE | BIB | Difference |
|---|---|---|---|
| 2025 | +24.7% | +59.3% | −34.6% |
| 2024 | +1.1% | −10.0% | +11.1% |
| 2023 | +3.7% | −1.3% | +5.0% |
| 2022 | −10.8% | −28.6% | +17.9% |
| 2021 | +1.6% | −5.9% | +7.5% |
| 2020 | +25.5% | +39.7% | −14.2% |
| 2019 | +18.3% | +45.5% | −27.3% |
| 2018 | +0.2% | −24.4% | +24.6% |
| 2017 | +22.4% | +40.8% | −18.3% |
| 2016 | −23.0% | −44.2% | +21.2% |
Source: Fund prospectus bar charts
Holdings overlap
9 of PBE's top 25 holdings also appear in BIB's top 25.
| Holding | PBE | BIB |
|---|---|---|
| Regeneron Pharmaceuticals, Inc. | 5.47% | 3.21% |
| Amgen Inc. | 5.22% | 4.48% |
| Vertex Pharmaceuticals Inc. | 4.99% | 4.65% |
| Biogen Inc. | 4.79% | 1.44% |
| Gilead Sciences, Inc. | 4.43% | 4.66% |
| United Therapeutics Corp. | 4.08% | 1.22% |
| Illumina, Inc. | 3.51% | 1.25% |
| Alnylam Pharmaceuticals, Inc. | 3.17% | 2.01% |
| Incyte Corp. | 3.06% | 0.97% |
Source: SEC Form N-PORT
PBE top 10
- Invesco Private Prime Fund — 12.89%
- Regeneron Pharmaceuticals, Inc. — 5.47%
- Amgen Inc. — 5.22%
- CareDx, Inc. — 5.04%
- Vertex Pharmaceuticals Inc. — 4.99%
- Invesco Private Government Fund — 4.97%
- Royalty Pharma PLC — 4.94%
- Biogen Inc. — 4.79%
- Gilead Sciences, Inc. — 4.43%
- United Therapeutics Corp. — 4.08%
BIB top 10
- N/a — 7.35%
- ProShares GENIUS Money Market ETF — 6.80%
- Gilead Sciences, Inc. — 4.66%
- Vertex Pharmaceuticals, Inc. — 4.65%
- Amgen, Inc. — 4.48%
- N/a — 3.94%
- N/a — 3.26%
- Regeneron Pharmaceuticals, Inc. — 3.21%
- N/a — 2.62%
- Alnylam Pharmaceuticals, Inc. — 2.01%
FAQ
What is the difference between PBE and BIB?
Which is cheaper, PBE or BIB?
Should I own both PBE and BIB?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.